Search and analyze individual stocks with comprehensive metrics
Strides Pharma Science Ltd
Fundamental Score
Strides Pharma Science Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of STAR across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (150.67%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Attractive Valuation (P/E: 19.35 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (79.67%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Excellent EPS Growth (122.76% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (124.04% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Strong Cash Generation (₹1000.52 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 41.49%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Risk Factors
2 factors identified
Low Promoter Commitment (27.86%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment and long-term vision alignment.
High Share Pledging Risk (44.13%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns or margin calls.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Strides Pharma Science Ltd
About STAR
Business Overview
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.
Company Details
Key Leadership
Corporate Events
Latest News
STAR Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Strides Pharma Science Ltd (STAR)?
As of 16 Jan 2026, 10:15 am IST, Strides Pharma Science Ltd (STAR) is currently trading at ₹900.10. The stock has a market capitalization of ₹8.41K (Cr).
Is STAR share price Overvalued or Undervalued?
STAR is currently trading at a P/E ratio of 19.35x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Strides Pharma Science Ltd share price?
Key factors influencing STAR's price include its quarterly earnings growth (Sales Growth: 4.62%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Strides Pharma Science Ltd a good stock for long-term investment?
Strides Pharma Science Ltd shows a 5-year Profit Growth of 124.04% and an ROE of 150.67%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.67 before investing.
How does Strides Pharma Science Ltd compare with its industry peers?
Strides Pharma Science Ltd competes with major peers in the Pharmaceuticals. Investors should compare STAR's P/E of 19.35x and ROE of 150.67% against the industry averages to determine its competitive standing.
What is the P/E ratio of STAR and what does it mean?
STAR has a P/E ratio of 19.35x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹19 for every ₹1 of annual earnings.
How is STAR performing according to Bull Run's analysis?
STAR has a Bull Run fundamental score of 31.7/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does STAR belong to?
STAR operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Strides Pharma Science Ltd.
What is Return on Equity (ROE) and why is it important for STAR?
STAR has an ROE of 150.67%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Strides Pharma Science Ltd generates profits from shareholders' equity.
How is STAR's debt-to-equity ratio and what does it indicate?
STAR has a debt-to-equity ratio of 0.67, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is STAR's dividend yield and is it a good dividend stock?
STAR offers a dividend yield of 0.44%, which means you receive ₹0.44 annual dividend for every ₹100 invested.
How has STAR grown over the past 5 years?
STAR has achieved 5-year growth rates of: Sales Growth 10.65%, Profit Growth 124.04%, and EPS Growth 122.76%.
What is the promoter holding in STAR and why does it matter?
Promoters hold 27.86% of STAR shares, with 44.13% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is STAR's market capitalization category?
STAR has a market capitalization of ₹8408 crores, placing it in the Mid-cap category.
How volatile is STAR stock?
STAR has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for STAR?
STAR has a 52-week high of ₹N/A and low of ₹N/A.
What is STAR's operating profit margin trend?
STAR has a 5-year average Operating Profit Margin (OPM) of 10.16%, indicating the company's operational efficiency.
How is STAR's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 4.62% and YoY Profit Growth of 79.67%.
What is the institutional holding pattern in STAR?
STAR has FII holding of 28.51% and DII holding of 12.98%. Significant institutional holding often suggests professional confidence in the stock.